Edgewise Therapeutics, Inc. (EWTX) News
Filter EWTX News Items
EWTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EWTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EWTX News From Around the Web
Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025BOULDER, Colo., January 07, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiovascular and muscular dystrophy programs and 2025 key milestones. |
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsGILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates. |
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder StudyData from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage. |
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness DiseaseOn Monday, Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that causes progressive muscle weakness. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read: Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thicken |
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)BOULDER, Colo., December 16, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. The trial met its primary endpoint of change from baseline in CK. |
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease ResearchBOULDER, Colo., December 05, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease Research. |
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024BOULDER, Colo., November 26, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. |
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBOULDER, Colo., November 07, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. |
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy NowWe recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […] |
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle SocietyBOULDER, Colo., October 01, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual Congress of the World Muscle Society (WMS) with an industry-sponsored symposium and the presentation of seven scientific posters. These presentations will highlight the effects of sevasemten in individuals with Becker based on findings from the DUNE and ARCH clinical trials, as well as provide perspec |